Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
09:47am, Thursday, 12'th May 2022
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
01:05pm, Thursday, 05'th May 2022 Zacks Investment Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 15.87% and 37.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity
11:00am, Friday, 01'st Apr 2022 GlobeNewswire Inc.
The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) The Company also announces completion of enroll
Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript
05:59pm, Tuesday, 15'th Mar 2022 Seeking Alpha
ALTIMMUNE INC (ALT) Q4 2021 Earnings Call Transcript
03:30pm, Tuesday, 15'th Mar 2022 The Motley Fool
ALT earnings call for the period ending December 31, 2021.
ALTIMMUNE INC (ALT) Q4 2021 Earnings Call Transcript
03:30pm, Tuesday, 15'th Mar 2022 The Motley Fool
ALT earnings call for the period ending December 31, 2021.
Altimmune stock falls ~5% despite Q4 beat
02:34pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Altimmune <> stock fell following its Q4 results, which beat analysts'' estimates.Q4 revenue rose +41.72% Y/Y to $3.28M
Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript
01:59pm, Tuesday, 15'th Mar 2022
Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript
Altimmune: Q4 Earnings Insights
01:52pm, Tuesday, 15'th Mar 2022 Benzinga
Altimmune (NASDAQ: ALT ) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Altimmune beat estimated earnings by 12.31%, reporting an EPS … Full story available on Benzinga.com
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
11:46am, Tuesday, 15'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne
Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph
Altimmune GAAP EPS of -$0.57 beats by $0.08, revenue of $3.28M beats by $3.19M
11:42am, Tuesday, 15'th Mar 2022 Seeking Alpha
Altimmune press release (ALT): Q4 GAAP EPS of -$0.57 beats by $0.08.Revenue of $3.28M (+42.0% Y/Y) beats by $3.19M.The company had cash, cash equivalents, short-term investments…
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
11:18am, Tuesday, 15'th Mar 2022
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
11:01am, Tuesday, 15'th Mar 2022 GlobeNewswire Inc.
Data readouts from multiple clinical trials expected during the next 6 to 12 months
Terra Surpassed Ethereum To Become Second Most Staked Asset
10:59am, Sunday, 13'th Mar 2022 DC Forecasts
Terra surpassed Ethereum to become the second most staked asset as LUNA’s price surge helped in the process so let’s read more today in our latest altcoin news. In addition, the data source reported the data showing that Terra surpassed Ethereum to become the second most staked asset which now has more than $28 billion […]
This Cross-Chain Crypto Asset Is One of Few Bullish Altcoins on the Market, According to Popular Analyst - The Daily Hodl
08:04am, Sunday, 13'th Mar 2022 The Daily Hodl
A closely followed crypto analyst says one mid-cap altcoin is one of the few digital assets on the market that''s currently showing bullish potential.
